In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on OS Therapies Incorporated (OSTX – Research Report), with a price target of $6.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Jason McCarthy has given his Buy rating due to a combination of factors surrounding OS Therapies Incorporated’s promising developments and strategic positioning. The company’s focus on its P2b program for OST-HER2 in recurrent osteosarcoma is progressing well, with full data expected soon, which could potentially lead to accelerated FDA approval. This innovative therapy utilizes a genetically engineered strain of Listeria to target HER2-expressing cancer cells, offering a unique approach to cancer immunotherapy.
Moreover, OST-HER2 has received several designations from the FDA, including orphan, fast-track, and rare pediatric disease designations, enhancing its potential market value and eligibility for the priority review voucher program. The positive top-line results from the P2b study, showing a significant improvement in 12-month event-free survival rates compared to historical controls, further bolster confidence in the program’s success. Additionally, the company’s valuation considers a potential commercialization of OST-HER2 in 2026, with adjustments for development and clinical trial risks, leading to a 12-month price target of $6.00.
In another report released on May 8, Lake Street also maintained a Buy rating on the stock with a $19.00 price target.
OSTX’s price has also changed slightly for the past six months – from $1.725 to $1.590, which is a -7.83% drop .